Valneva SE Granted Conditional Marketing Authorization for its COVID-19 Vaccine Candidate
Apr 14, 2022 By MarketDepth
Valneva SE (Nasdaq: VALN) today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom has granted Conditional Marketing Authorization (CMA) for its inactivated whole-virus COVID-19 vaccine candidate, VLA2001.
Shares up 8%
Shares of Valneva SE (Nasdaq: VALN) gained over 8% during the premarket trading session.
MHRA found that VLA2001 meets the required safety, quality and effectiveness standards.
“We are extremely pleased with this new authorization and would like to thank the MHRA for their trust and confidence. VLA2001 is the only inactivated whole virus COVID-19 vaccine approved in the UK and this authorization could pave the way for the availability of an alternative vaccine solution for the UK population. We continue to receive messages every day from people who are looking for a more traditional vaccine approach. We believe that this new approval could also lead to additional marketing authorizations in other regions of the world. I would like to personally thank all the people who have been supporting us in this endeavor and our internal teams for all their hard work.”
Thomas Lingelbach, Chief Executive Officer of Valneva
The newly acquired marketing authorization comes in addition to the emergency use authorization which was granted by the Bahraini NHRA in March 2022.
